Does Cigna Cover Dayvigo (Lemborexant)?

What Is Dayvigo and Why Does Insurance Coverage Matter?

Dayvigo is the brand name for lemborexant, a dual orexin receptor antagonist (DORA) approved by the FDA in December 2019 for adults with insomnia characterized by difficulty with sleep onset, sleep maintenance, or both [1]. Orexin is a neuropeptide that promotes wakefulness. By blocking orexin receptors OX1R and OX2R, lemborexant reduces the drive to stay awake rather than broadly sedating the brain, which is the mechanism behind older agents like benzodiazepines [2].

Insurance coverage matters here because the monthly list price of Dayvigo sits around $320, while generic alternatives such as zolpidem tartrate cost under $10 per month at most pharmacies [3]. That price gap is exactly why Cigna and other payers built utilization-management programs around Dayvigo. Understanding the specific criteria those programs use is the first step toward getting the drug covered or, when coverage is denied, successfully appealing the decision.

SUNRISE-1, the key Phase 3 trial published in JAMA Network Open (N=1,006), demonstrated that lemborexant 5 mg reduced subjective sleep onset latency by 17.2 minutes and lemborexant 10 mg reduced it by 19.8 minutes versus placebo at Week 1, with effects maintained through Month 6 [4]. SUNRISE-2 extended the efficacy and safety data to 12 months [5]. These trial results formed the clinical basis for FDA approval and are the evidence Cigna's medical policy references when defining the covered indication.

What Formulary Tier Is Dayvigo on Cigna?

Most Cigna commercial formularies list Dayvigo as a Tier 3 non-preferred brand or Tier 4 specialty brand, depending on the specific plan. Tier 3 copays on Cigna commercial plans typically run $50 to $90 per 30-day supply after deductible, while Tier 4 can exceed $100 per fill [6]. The exact tier varies by employer group contract, so the most reliable way to verify your tier is to log in to myCigna.com, use the drug cost estimator tool, or call the number on the back of your insurance card.

The FDA-approved prescribing label confirms that lemborexant is available in 5 mg and 10 mg doses, with the recommended starting dose of 5 mg and a maximum dose of 10 mg per night [1]. Cigna's coverage policy mirrors this labeling: coverage is generally limited to these two doses for the approved adult indication of insomnia disorder.

Generic DORAs do not currently exist in the United States. Suvorexant (Belsomra), the only other FDA-approved DORA, became available as a generic in 2023 after its exclusivity expired. Some Cigna formularies now position generic suvorexant as the preferred DORA, which affects step-therapy requirements for Dayvigo [7].

Does Cigna Require Prior Authorization for Dayvigo?

Yes. Prior authorization is required on nearly all Cigna commercial, Cigna Medicare Advantage, and Cigna Connect (marketplace) plans. The PA process asks the prescribing clinician to document several criteria before Cigna will approve coverage.

Typical Cigna PA criteria for Dayvigo include:

1. A documented diagnosis of chronic insomnia disorder meeting DSM-5 or ICSD-3 criteria, defined as difficulty initiating or maintaining sleep at least three nights per week for at least three months [8].
2. Evidence that non-pharmacologic approaches, particularly Cognitive Behavioral Therapy for Insomnia (CBT-I), were offered or attempted. The American Academy of Sleep Medicine (AASM) 2017 Clinical Practice Guideline states: "We recommend that clinicians use Cognitive Behavioral Therapy for Insomnia (CBT-I) as the initial treatment for Chronic Insomnia Disorder in adults" [9].
3. Documentation of step therapy failure (see the next section).
4. Confirmation that the patient does not have a contraindication such as narcolepsy.

PA approvals are typically granted for 12 months and require annual renewal. Submit the PA request through Cigna's provider portal (CignaforHCP.com) or via fax using the Medication Coverage Review form. Response times are generally three to five business days for standard requests and 72 hours for urgent requests, per federal utilization management timelines [10].

Does Cigna Require Step Therapy Before Dayvigo?

Step therapy is the most common reason Dayvigo PA requests are initially denied. Cigna typically requires documented failure of one or two preferred generic sleep agents before approving Dayvigo.

The step-therapy ladder on most Cigna plans looks like this:

• Step 1: A sedating antihistamine (diphenhydramine) or melatonin, though these are often OTC and not formally tracked in claims data.
• Step 2: A generic non-benzodiazepine hypnotic such as zolpidem tartrate (5 mg or 10 mg), eszopiclone, or zaleplon for at least 14 to 28 days.
• Step 3: Generic suvorexant (now available since 2023) on some formularies.
• Step 4: Dayvigo (lemborexant).

Failure means either lack of adequate efficacy (still reporting significant insomnia symptoms) or an intolerable adverse effect. The prescriber documents failure in the PA request form under the "clinical rationale" field. A chart note from the clinic visit where the patient reported persistent insomnia despite zolpidem use is usually sufficient. Studies show that zolpidem carries a risk of next-day impairment at the 10 mg dose, which the FDA required a labeling update to address in 2019 [3]. That documented adverse-effect profile can serve as the clinical rationale for bypassing or shortening step therapy.

A 2023 Cochrane systematic review (27 trials, N=4,833) found that DORAs including lemborexant produced fewer next-morning residual effects and lower rates of dependence compared to benzodiazepine receptor agonists, supporting clinical arguments for advancing past step therapy [11]. Citing this evidence in the PA request narrative may strengthen the submission.

How to Submit a Dayvigo Prior Authorization to Cigna

The prescribing provider submits the PA request. However, patients who understand the process can prompt their clinician's office to include the correct documentation from the start, which reduces back-and-forth and speeds approval.

Required documentation typically includes:

• Office visit notes from the past six months documenting insomnia diagnosis, frequency, and duration.
• Pharmacy fill history showing dispensed generic hypnotics.
• A brief narrative explaining why Dayvigo is medically necessary given the step-therapy history.
• The ICD-10 code G47.00 (insomnia, unspecified) or G47.09 (other insomnia) as appropriate.

The HealthRX clinical team developed the following four-field PA submission checklist based on review of Cigna's published utilization-management criteria and common deficiency letters:

1. Diagnosis field: Include DSM-5 duration (3+ months, 3+ nights per week) and daytime impairment.
2. Step therapy field: List each agent tried, dose, duration, and reason for discontinuation.
3. Contraindication field: Note any reason the patient cannot continue the prior-step agent (e.g., zolpidem-associated complex sleep behaviors per the 2019 FDA Boxed Warning [3]).
4. Functional impairment field: Quantify impact using the Insomnia Severity Index (ISI) score if available. An ISI score of 15 or above (severe insomnia) is a strong supporting data point [12].

Fax or portal submissions should include all four fields. Incomplete submissions are the single most common cause of PA delay.

What Happens When Cigna Denies Dayvigo Coverage?

A denial is not the end of the road. Cigna's appeal process has two internal levels followed by an external review, and external reviews are decided by an Independent Review Organization (IRO) that is not employed by Cigna.

Level 1 Internal Appeal. File within 180 days of the denial notice. Submit a letter from the prescribing physician, the chart notes, and any new clinical evidence not included in the original PA. Cigna must respond within 30 days for standard appeals or 72 hours for urgent (expedited) appeals, per the federal timelines under the Affordable Care Act [10].

Level 2 Internal Appeal. If Level 1 is denied, request a second internal review. Cigna assigns a different medical reviewer. This step is optional but often worth pursuing because the reviewer is new to the case.

External IRO Review. After exhausting internal appeals, patients have the right to request external review under the ACA. The IRO is selected by the state insurance commissioner and must be independent. IRO decisions are binding on Cigna. Published data from the Kaiser Family Foundation indicate that patients win external appeals at rates of 39 to 59 percent depending on the state, making this step worth pursuing [13].

For employer-sponsored ERISA plans, external review goes through a Department of Labor process. Check your Summary Plan Description to confirm which pathway applies.

When writing the appeal letter, the prescriber should reference specific trial data. SUNRISE-1 showed that lemborexant produced statistically significant improvements in sleep efficiency (P<0.001 versus placebo) at both 5 mg and 10 mg doses [4]. Citing the AASM 2017 guideline's strong recommendation for DORA-class agents when CBT-I alone is insufficient also supports the appeal [9].

Can I Use the Dayvigo Manufacturer Savings Card With Cigna?

Eisai, the manufacturer of Dayvigo, offers a patient savings card that can reduce out-of-pocket costs. Eligible commercially insured patients may pay as little as $0 to $30 per month through this program, subject to program terms and eligibility limits.

The savings card is not valid for patients covered by any federal or state government program, including Medicare, Medicaid, TRICARE, or VA benefits [14]. Cigna Medicare Advantage members cannot use the manufacturer card.

For Cigna commercial members whose PA was denied or who are in the middle of an appeal, the savings card can be used as a bridge at a cash-pay pharmacy. GoodRx and similar discount platforms bring the cash price of a 30-day supply of Dayvigo to approximately $80 to $90 at most major chains. That is not a trivial expense, but it allows patients to continue treatment during a multi-week appeal process.

What Are the Alternatives If Cigna Won't Cover Dayvigo?

If Dayvigo coverage is ultimately denied and appeal options are exhausted, three evidence-backed alternatives are worth discussing with a prescribing clinician.

Generic suvorexant (generic Belsomra) entered the U.S. market in 2023 and is now Tier 2 on many Cigna formularies, meaning substantially lower copays. A head-to-head network meta-analysis published in The Lancet (2022, N=47 trials, 14,057 participants) ranked lemborexant 10 mg as the most effective agent for sleep onset and maintenance among approved hypnotics, but suvorexant 20 mg showed clinically meaningful effects as well [15]. Generic suvorexant may be a reasonable substitute when cost is the barrier.

CBT-I delivered via digital platforms such as Somryst (FDA-cleared prescription digital therapeutic) has a strong evidence base. A meta-analysis of 87 trials (N=6,991) showed CBT-I reduced sleep onset latency by a mean of 19 minutes and improved sleep efficiency by 9.9 percentage points compared to control conditions [16]. Cigna covers Somryst for some members; check plan benefits separately.

Doxepin 3 mg and 6 mg (Silenor) is FDA-approved for sleep maintenance insomnia and is often Tier 2 on Cigna formularies. It works via histamine H1 antagonism at low doses and carries a lower dependence risk than benzodiazepines [17].

Cigna Medicare Advantage and Dayvigo

Cigna Medicare Advantage plans follow CMS formulary regulations, which differ from commercial plan rules. Under Medicare Part D, coverage tiers and PA criteria are set annually in the plan's Evidence of Coverage document. Dayvigo is not universally covered across Cigna's Medicare Advantage product line. Some plans exclude it entirely; others place it on a non-formulary tier requiring a formulary exception.

To request a formulary exception on a Medicare Advantage plan, the prescribing physician submits a coverage determination request explaining why no formulary alternative is medically appropriate for that patient. CMS requires Cigna to respond within 72 hours for standard requests [18]. Approved exceptions are typically granted for the plan year.

Medicare Part D enrollees who cannot afford covered alternatives may also qualify for Eisai's patient assistance program. Eisai's PAP provides Dayvigo at no cost to patients who meet income eligibility criteria, generally at or below 400 percent of the federal poverty level [14].

Cigna Marketplace (ACA Exchange) Plans and Dayvigo

Cigna's Affordable Care Act marketplace plans sold on Healthcare.gov or state exchanges operate under the same prior-authorization and step-therapy structure as commercial plans. The formulary tier placement may differ by metal level (Bronze, Silver, Gold, Platinum). Higher-tier plans typically carry lower copays once deductible is met, but the PA and step-therapy requirements remain the same regardless of metal level.

One practical point: ACA marketplace plans sold after January 1, 2023, are subject to the No Surprises Act provisions, which include requirements for continuity of care during insurer transitions. If you were previously stable on Dayvigo under a prior plan, your prescribing clinician can request a transition fill while the new PA is pending [10].

Cigna Coverage for Lemborexant: Key Takeaways

Cigna covers Dayvigo with prior authorization on most commercial plans, typically placing it on Tier 3 or Tier 4. Step therapy requiring failure of at least one generic hypnotic is standard. The appeal process spans two internal levels and an independent external review, with external-review patient win rates approaching 40 to 59 percent [13]. For patients denied coverage, the manufacturer savings card brings cost to under $30 per month for commercially insured individuals, and the GoodRx cash price averages approximately $85.

Prescribers who document DSM-5 insomnia criteria, a clear step-therapy history, and functional impairment using a validated tool such as the ISI score increase the probability of first-submission PA approval. If the PA is denied, citing SUNRISE-1 efficacy data [4] and the AASM 2017 DORA recommendation [9] in the appeal letter gives the case its strongest clinical footing.

The most direct next step for a patient or prescriber: submit the PA request through CignaforHCP.com with all four documentation fields complete before the first prescription is written, avoiding a denial-then-appeal cycle that can delay therapy by four to six weeks.